

February 20, 2017
130 E Aurora Ave
Des Moines, Iowa 50313-3654

Andrew Funk, Executive Director
Iowa Board of Pharmacy
400 S.W. Eighth Street, Suite E
Des Moines, IA 50309-4688

Dear Mr. Funk,

Thank you for responding to my letter of February 19, 2017, regarding SF 282.

<https://www.legis.iowa.gov/legislation/BillBook?ga=87&ba=sf282>

I would like the pharmacy board to review the legislation (SF 282) and take a position in favor, again, or neutral on section 1 of the bill.

Of course, if the board wishes, it can take a position on sections 2 and 3 of the bill as well (although I don't think those two sections are controversial).

I would like to have notice in advance of the meeting so I can make arrangements with my employer to attend.

I really don't anticipate speaking on this.

I think my letter speaks for itself.

I'm just interested in hearing the board's thoughts.

In the meantime, the formal letter I sent you yesterday is a good tool for me to use in talking with legislators (so it serves a purpose).

Both Congressman Young and Senator Whitver thought the bill was directed at the cannabidiol product, Epidiolex.

Since I am aware of Epidiolex, that does seem possible. However, I was unaware that the DEA had already decided what schedule it will be in.

Please send me whatever information you have that predetermines the schedule Epidiolex will be placed in by the DEA. I have not seen that before.

Thank you!

Sincerely,

Carl Olsen
130 E Aurora Ave
Des Moines, Iowa 50313-3654
515-343-9933
carl-olsen@mchsi.com